Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prothena
Biotech
UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2
UCB’s Novartis-partnered oral small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2 trial.
Gabrielle Masson
Dec 16, 2024 3:19pm
Prothena promotes one exec while another leaves—Chutes & Ladders
Oct 4, 2024 8:00am
NIH leader's research misconduct calls drugs into question
Sep 26, 2024 9:12am
Bristol Myers checks 'yes' on Prothena neurodegenerative therapy
May 29, 2024 10:38am
BMS pays $95M to exercise Evotec, Prothena neuroscience options
Jul 11, 2023 5:30am
Prothena teams with Walgreens to accelerate Alzheimer's trial
Apr 13, 2023 9:55am
